Abstract
Long-term treatment with the dopamine precursor levodopa (L-DOPA) induces dyskinesia in Parkinson's disease (PD) patients. We divided hemiparkinsonian rats treated chronically with L-DOPA into two groups: one showed motor improvement without dyskinesia, and the other developed debilitating dyskinesias in response to the treatment. We then compared the plasticity of corticostriatal synapses between the two groups. High-frequency stimulation of cortical afferents induced long-term potentiation (LTP) of corticostriatal synapses in both groups of animals. Control and non-dyskinetic rats showed synaptic depotentiation in response to subsequent low-frequency synaptic stimulation, but dyskinetic rats did not. The depotentiation seen in both L-DOPA–treated non-dyskinetic rats and intact controls was prevented by activation of the D1 subclass of dopamine receptors or inhibition of protein phosphatases. The striata of dyskinetic rats contained abnormally high levels of phospho[Thr34]-DARPP-32, an inhibitor of protein phosphatase 1. These results indicate that abnormal information storage in corticostriatal synapses is linked with the development of L-DOPA–induced dyskinesia.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Marsden, C.D. Basal ganglia diseases. Lancet 2, 1141–1147 (1986).
Lang, A.P. & Lozano, A.E. Parkinson's disease. N. Engl. J. Med. 339, 1044–1053 (1998).
Obeso, J.A., Olanow, C.W. & Nutt, J.C. Levodopa motor complications in Parkinson's disease. Trends Neurosci. 23, 2–7 (2000).
Bezard, E., Brotchie, J.M. & Gross, C.E. Pathophysiology of levodopa-induced dyskinesia: potential for new therapies. Nat. Rev. Neurosci. 2, 577–588 (2001).
Calabresi, P., Giacomini, P., Centonze, D. & Bernardi, G. Levodopa-induced dyskinesia: a pathological form of striatal synaptic plasticity? Ann. Neurol. 47, 60–68 (2000).
Bedard, P.J. et al. Pathophysiology of L-dopa-induced dyskinesias. Mov. Disord. 14, 4–8 (1999).
Chase, T.N. & Oh, J.D. Striatal dopamine- and glutamate-mediated dysregulation in experimental parkinsonism. Trends Neurosci. 23, 86–91 (2000).
Graybiel, A.M. Building action repertoires: memory and learning functions of the basal ganglia. Curr. Opin. Neurobiol. 5, 733–741 (1995).
Schwarting, R.K. & Huston, J.P. The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments. Prog. Neurobiol. 50, 275–331 (1996).
Cenci, M.A., Lee, C.S. & Björklund, A. L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur. J. Neurosci. 10, 2694–2706 (1998).
Lundblad, M. et al. Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. Eur. J. Neurosci. 15, 120–132 (2002).
Hagell, P. & Widner, H. Clinical rating of dyskinesias in Parkinson's disease: use and reliability of a new rating scale. Mov. Disord. 14, 448–455 (1999).
Calabresi, P., Centonze, D. & Bernardi, G. Electrophysiology of dopamine in normal and denervated striatal neurons. Trends Neurosci. 23, 57–63 (2000).
Calabresi, P., Pisani, A., Mercuri, N.B. & Bernardi, G. The corticostriatal projection: from plasticity to basal ganglia disorders. Trends Neurosci. 19, 19–24 (1996).
Ingham, C.A., Hood, S.H., Taggart, P. & Arbuthnott, G.W. Plasticity of synapses in the rat neostriatum after unilateral lesion of the nigrostriatal dopaminergic pathway. J. Neurosci. 18, 4732–4743 (1998).
Calabresi, P., Pisani, A., Mercuri, N.B. & Bernardi, G. Long-term potentiation in the striatum unmasked by removing the voltage-dependent magnesium block of NMDA receptor channels. Eur. J. Neurosci. 4, 929–935 (1992).
Charpier, S. & Deniau, J.M. In vivo activity-dependent plasticity at cortico-striatal connections: evidence for physiological long-term potentiation. Proc. Natl. Acad. Sci. USA 94, 7036–7040 (1997).
Reynolds, J.N., Hyland, B.I. & Wickens, J.R. A cellular mechanism of reward-related learning. Nature 413, 67–70 (2001).
Calabresi, P. et al. Dopamine and cAMP-regulated phosphoprotein 32 kDa controls both striatal long-term depression and long-term potentiation, opposing forms of synaptic plasticity. J. Neurosci. 20, 8443–8451 (2000).
Centonze, D. et al. Unilateral dopamine denervation blocks corticostriatal LTP. J. Neurophysiol. 82, 3575–3579 (1999).
Kerr, J.N. & Wickens, J.R. Dopamine D-1/D-5 receptor activation is required for long-term potentiation in the rat neostriatum in vitro. J. Neurophysiol. 85, 117–124 (2001).
Huang, C.C. & Hsu, K.S. Progress in understanding the factors regulating reversibility of long-term potentiation. Rev. Neurosci. 12, 51–68 (2001).
Fujii, S., Saito, K., Miyakawa, H., Ito, K. & Kato, H. Reversal of long-term potentiation (depotentiation) induced by tetanus stimulation of the input to CA1 neurons of guinea pig hippocampal slices. Brain Res. 555, 112–122 (1991).
Bashir, Z.I. & Collingridge, G.L. An investigation of depotentiation of long-term potentiation in the CA1 region of the hippocampus. Exp. Brain Res. 100, 437–443 (1994).
O'Dell, T.J. & Kandel, E.R. Low-frequency stimulation erases LTP through an NMDA receptor-mediated activation of protein phosphatases. Learn. Mem. 1, 129–139 (1994).
Mulkey, R.M., Endol, S., Shenolikar, S. & Malenka, R.C. Involvement of a calcineurin/inhibitor-1 phosphatase cascade in hippocampal long-term depression. Nature 369, 486–488 (1994).
Otmakhova, N.A. & Lisman, J.E. D1/D5 dopamine receptors inhibit depotentiation at CA1 synapses via cAMP-dependent mechanism. J. Neurosci. 18, 1270–1279 (1998).
Huang, C.C., Liang, Y.C. & Hsu, K.S. Characterization of the mechanism underlying the reversal of long term potentiation by low frequency stimulation at hippocampal CA1 synapses. J. Biol. Chem. 276, 48108–48117 (2001).
Hemmings, H.C., Greengard, P., Tung, H.Y.L. & Cohen, P. DARPP-32, a dopamine-regulated neuronal phosphoprotein, is a potent inhibitor of protein phosphatase-1. Nature 310, 503–505 (1984).
Greengard, P., Allen, P.B. & Nairn, A.C. Beyond the dopamine receptor: the DARPP-32/protein phosphatase-1 cascade. Neuron 23, 435–447 (1999).
Jankovic, J. Levodopa strengths and weaknesses. Neurology 58, S19–S32 (2002).
Schmidt, R.H., Ingvar, M., Lindvall, O., Stenevi, U. & Bjorklund, A. Functional activity of substantia nigra grafts reinnervating the striatum: neurotransmitter metabolism and [14C]2-deoxy-D-glucose autoradiography. J. Neurochem. 38, 737–748 (1982).
Andersson, M., Hilbertson, A. & Cenci, M.A. Striatal fosB expression is causally linked with L-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson's disease. Neurobiol. Dis. 6, 461–474 (1999).
Schallert, T., Fleming, S.M., Leasure, J.L., Tillerson, J.L. & Bland, S.T. CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury. Neuropharmacology 39, 777–787 (2000).
Rozas, G., Guerra, M.J. & Labandeira-Garcia, J.L. An automated rotarod method for quantitative drug-free evaluation of overall motor deficits in rat models of parkinsonism. Brain Res. Prot. 2, 75–84 (1997).
Svenningson, P. et al. Regulation of the phosphorylation of the dopamine- and cAMP-regulated phosphoprotein of 32 kDa in vivo by dopamine D1, dopamine D2 and adenosine A2A receptors. Proc. Natl. Acad. Sci. USA 97, 1856–1860 (2000).
Hemmings, H.C. & Greengard, P. DARPP-32, a dopamine- and adenosine 3′:5′-monophosphate-regulated phosphoprotein: regional, tissue, and phylogenetic distribution. J. Neurosci. 6, 1469–1481 (1986).
Acknowledgements
The authors wish to thank M. Tolu for technical assistance. This work was supported by a CNR Neurobiotecnologie–FISR and a Telethon grant GGP02035 (P.C.), by the Swedish Research Council (G.F. and M.A.C.), by National Institutes of Health grants MH40899 and DA10044 (P.G.) and by The Kocks′ Foundation and The Swedish Association of the Neurologically Disabled (M.A.C.).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Picconi, B., Centonze, D., Håkansson, K. et al. Loss of bidirectional striatal synaptic plasticity in L-DOPA–induced dyskinesia. Nat Neurosci 6, 501–506 (2003). https://doi.org/10.1038/nn1040
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nn1040
This article is cited by
-
Impaired cognitive and motor function are coincident with l-DOPA-induced dyskinesia in a model of Parkinson’s disease
Scientific Reports (2023)
-
Cross-modality supervised image restoration enables nanoscale tracking of synaptic plasticity in living mice
Nature Methods (2023)
-
Dopamine and Glutamate Crosstalk Worsen the Seizure Outcome in TLE-HS Patients
Molecular Neurobiology (2023)
-
The Dynamics of Dopamine D2 Receptor-Expressing Striatal Neurons and the Downstream Circuit Underlying L-Dopa-Induced Dyskinesia in Rats
Neuroscience Bulletin (2023)
-
Cerebellar stimulation prevents Levodopa-induced dyskinesia in mice and normalizes activity in a motor network
Nature Communications (2022)